Möglichkeiten und Probleme der Diagnostik und Therapie des Endometriumkarzinoms

  • Albrecht Pfleiderer
Part of the AGO Arbeitsgemeinschaft für Gynäkologische Onkologie book series (AGO)


Hier wird versucht, die wichtigsten Publikationen und Erkenntnisse aus den Jahren 1989 und 1990 zum Thema Endometriumkarzinom zu referieren, um so einen aktuellen Überblick über die Diagnostik und die Therapie dieses Karzinoms im August 1990 zu fixieren.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aalders J, Abeler V, Kolstad P, Onsrud U: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet. Gynecol. 56: 419–427, 1980PubMedGoogle Scholar
  2. 2.
    Annual Report on the results of treatment in gynecological cancer: Pettersson F, ed. Vol.XX, Stockholm 1988Google Scholar
  3. 3.
    Bauknecht T, Kohler M, Janz I, Pfleiderer A: The occurrence of epidermal Growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. EGF receptors and factors in gynecological carcinomas. J. Cancer Res. Clin. Oncol. 115: 193–9, 1989PubMedCrossRefGoogle Scholar
  4. 4.
    Belloni C, Vigano R, del Maschio A, Sironi S, Taccagni Gl, Vignali M: Magnetic resonance imaging in endometrial carcinoma staging. Gynecol. Oncol. 37: 172–7, 1990PubMedCrossRefGoogle Scholar
  5. 5.
    Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke-Pearson DL, Bast RC Jr, McCarty KS Jr: Epidermal growth factor receptor expression in normal and malignant endometrium. Am J. Obstet. Gynecol. 161: 1247–52, 1989PubMedGoogle Scholar
  6. 6.
    Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15: 10–17, 1983PubMedCrossRefGoogle Scholar
  7. 7.
    Bonte J: Results of adjuvant hormonotherapy in early endometrial carcinomas and of curative hormonotherapy in advanced or recurrent cancers by means of progestagens and antiestrogens, pp 250–255 in: Bolla M et al eds.: Endometrial cancers, Karger, Basel 1986Google Scholar
  8. 8.
    Borazjani G, Twiggs LB, Leung BS, Prem KA, Adcock LL, Carson LF: Prognostic significance of steroid receptors measured in primary metastatic and recurrent endometrial carcinoma. Am J. Obstet. Gynecol. 161: 1253–7, 1989PubMedGoogle Scholar
  9. 9.
    Britton LC, Wilson TO, Gaffey TA, Lieber MM, Wieand HS, Podratz KC: Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol. Oncol. 34: 317–22, 1989PubMedCrossRefGoogle Scholar
  10. 10.
    Cacciatore B, Lehtovirta P, Wahlstrom T, Ylanen K, Ylostalo P: Contribution of vaginal scanning to sonographic evaluation of endometrial cancer invasion. Acta Oncol. 28: 585–8, 1989PubMedCrossRefGoogle Scholar
  11. 11.
    Chen SS, Rumancik WM, Spiegel G: Magnetic resonance imaging in stage I endometrial carcinoma. Obstet. Gynecol. 75: 274–7, 1990PubMedGoogle Scholar
  12. 12.
    Creasman WT, Soper JT, McCarty KS jr et al: Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Amer. J. Obstet. Gynecol. 151: 922–32, 1985Google Scholar
  13. 13.
    Deppe G: Chemotherapy of gynecologic cancer, p. 158 Wiley-Liss, New York 1990Google Scholar
  14. 14.
    Einhorn N: The role of preoperative radiotherapy in the treatment of carcinoma of the endometrium, pp 53–61 in: Surwit EA and Alberts DS: Endometrial cancer. Kluwer Acad. Publ. Boston 1989Google Scholar
  15. 15.
    Fanning J, Tsukada Y, Piver MS: Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol. Oncol. 37: 47–50, 1990PubMedCrossRefGoogle Scholar
  16. 16.
    Feichter GE, Höffken H, Hepp J, Haag D, Heberling D et al: DNA-flow- cytometric measurements on the normal, atrophic, hyperplastic and neoplastic human endometrium. Virchows Arch. 398: 53–65, 1982CrossRefGoogle Scholar
  17. 17.
    Fekete M, Wittliff JL, Schally AV: Characteristics and distribution of receptors for (D-Top)-luteinizing-hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J. Clin. Lab. Anal. 3: 137–147, 1989PubMedCrossRefGoogle Scholar
  18. 18.
    Goff BA, Rice LW: Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol. Oncol. 38: 46–48, 1990PubMedCrossRefGoogle Scholar
  19. 19.
    Gordon AN, Fleischer AC, Dudley BS, Drolshagan LF, Kalemeris GC, Partain CL, Jones HW, Burnett LS: Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography and magnetic resonance imaging. Gynecol Oncol. 34: 175–9, 1989PubMedCrossRefGoogle Scholar
  20. 20.
    Kauppila A, Kujansuu E, Vihko R: Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestin, clinical correlates. Cancer 50: 2157–62, 1982PubMedCrossRefGoogle Scholar
  21. 21.
    Kleine W, Fuchs A, de Gregorio G, Geyer H: Östrogen- und Progesteronrezeptoren beim Korpuskarzinom und ihre klinische Bedeutung. Geburtsh. u. Frauenheilk. 42: 884–7, 1982CrossRefGoogle Scholar
  22. 22.
    Kleine W, Maier T, Geyer H, Pfleiderer A: Estrogen and Progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol. Oncol. 38: 59–65, 1990PubMedCrossRefGoogle Scholar
  23. 23.
    K0SS LG, Schreiber K, Oberländer SG et al: Screening of asymptomatic women for endometrial cancer. Obstet. Gynecol. 57: 681–91, 1981PubMedGoogle Scholar
  24. 24.
    Lee KR, Scully RE: Complex endometrial hyperplasia and carcinoma in adolescents and young women 15 to 20 years of age. A report of 10 cases. Int. J. Gynecol. Pathol. 8: 201–13, 1989PubMedCrossRefGoogle Scholar
  25. 25.
    Lewandowski G, Torrisi J, Potkul RK, Holloway RW, Popescu G, Whitfield G, Delgado G: Hysterectomy with extended surgical staging and radiotherapy versus hysterectomy alone and radiotherapy in stage I endometrial cancer: A comparison of complication rates. Gynecol. Oncol. 36: 401–4, 1990PubMedCrossRefGoogle Scholar
  26. 26.
    Lindahl B, Alm P, Ferno M, Killander D, Langstrom E, Norgren A, Trope C: Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in stage I-II endometrial carcinoma. Acta Oncol. 28: 595–9, 1989PubMedCrossRefGoogle Scholar
  27. 27.
    Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback NB, Kurman R, Thipgen JT: Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: A gynecologic oncology group study. Gynecol. Oncol. 36: 166–71, 1990PubMedCrossRefGoogle Scholar
  28. 28.
    Osmers R, Volksen M, Schauer A: Vaginosonography for early detection of endometrial carcinoma? Lancet, 335 (8705): 1569–71, 1990PubMedCrossRefGoogle Scholar
  29. 29.
    Pfleiderer A, Kleine W: Risk factors of endometrial carcinoma, pp 12–21 in: Bolla M et al eds: Endometrial cancers, Karger, Basel 1986Google Scholar
  30. 30.
    Pfleiderer A, Kleine W, König P, Geyer H: Hormonal receptors in endometrial cancer. Analysis of clinical prognosis and risk factors, pp 35–46 in: Wolff JP, Scott JS eds: Hormones and sexual factors in human cancer aetiology. Elsevier SC. Publ., 1984Google Scholar
  31. 31.
    Pfleiderer A, Kleine W: Surgical methods and significance of different prognostic criteria, pp 119–128 in: Schulz KD et al eds: Endometrial cancer. W. Zuckschwerdt, München, 1986Google Scholar
  32. 32.
    Pfleiderer A: Der heutige Stand der Therapie des Korpuskarzinoms, pp 117–136 in: Künzel W u. Gips H eds: Gießener gynäkologische Fortbildung 1987, Springer Verlag Berlin, Heidelberg 1987CrossRefGoogle Scholar
  33. 33.
    Pfleiderer A: Endometrial malignancy. Current opinion in Obstetrics and Gynecology Vol. 3, No. 1, February 1991 (in press)Google Scholar
  34. 34.
    Pliskow S, Penalver M, Averette HE: Stage III and IV endometrial carcinoma: A review of 41 cases. Gynecol. Oncol. 38: 210–215, 1990PubMedCrossRefGoogle Scholar
  35. 35.
    Rosenberg P, Wingren S, Simonsen E, Stal O, Risberg B, Nordenskjold B: Flow cytometric measurements of DNA index and S-Phase on paraffin- embedded early stage endometrial cancer: An important prognostic indicator Gynecol. Oncol. 35: 50–4, 1989PubMedCrossRefGoogle Scholar
  36. 36.
    Sainsburg JR, Farndon JR, Needham GK et al: Epidermal-growth-factor receptor status as predictor of early recurrence and of death from breast cancer. Lancet I, 364–6, 1985CrossRefGoogle Scholar
  37. 37.
    Schally AV, Comaru-Schally AM, Redding TW: Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc. Soc. Exp. Biol. Med. 175: 259–281, 1984PubMedGoogle Scholar
  38. 38.
    Sorbe BG, Smeds AC: Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I. Int. J. Radiat. Oncol. Biol. Phys. 18: 305–14, 1990PubMedCrossRefGoogle Scholar
  39. 39.
    Srkalovic G, Wittliff JL, Schally AV: Detection and partial characterization of receptors for (D-TRP6)-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res. 50: 1841–6, 1990PubMedGoogle Scholar
  40. 40.
    Thigpen JT, Blessing JA: Progestin therapy for advanced or recurrent endometrial carcinoma: the gynecologic oncology group experience. Referat: Progestin Action and Progesteron Receptors in breast cancer, April 6–7, 1989, Washington DC, NCI, AGGoogle Scholar
  41. 41.
    Thorvinger B, Gudmundsson T, Horvat G, Forsberg L, Holtas S: Staging in local endometrial carcinoma. Assessment of magnetic resonance and ultrasound examinations. Acta Radiol: 30: 525–9, 1989PubMedCrossRefGoogle Scholar
  42. 42.
    Vergote I, Kjorstad K, Abeler V, Kolstad P: A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64: 1011–6, 1989PubMedCrossRefGoogle Scholar
  43. 43.
    Wilson TO, Podratz KC, Gaffey TA, Malkasian GD Jr, O#x2019;Brien PC, Naessens JM: Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet. Gynecol. 162: 418–23, discussion 423–6, 1990PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Albrecht Pfleiderer

There are no affiliations available

Personalised recommendations